Imfinzi

AstraZeneca Shows It Can Still Take Some Knocks
AstraZeneca Shows It Can Still Take Some Knocks
Yahoo/Bloomberg
AstraZeneca
Imfinzi
Flag link:
Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
CP Wire
AstraZeneca
MedImmune
Imfinzi
non-small cell lung cancer
Flag link:
Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
AstraZeneca
Imfinzi
non-small cell lung cancer
Flag link:
Major Expected Events from AstraZeneca’s R&D in H2 2018
Major Expected Events from AstraZeneca’s R&D in H2 2018
Market Realist
AstraZeneca
China
Lynparza
Tagrisso
Imfinzi
Flag link:
Hitting cancer early: AstraZeneca's bid to outmaneuver rivals
Hitting cancer early: AstraZeneca's bid to outmaneuver rivals
Yahoo/Reuters
AstraZeneca
Pascal Soriot
cancer
Imfinzi
Flag link:
AstraZeneca wins speedy approvals for cancer drugs in Japan
AstraZeneca wins speedy approvals for cancer drugs in Japan
Yahoo/Reuters
AstraZeneca
Japan
Imfinzi
Lynparza
Flag link:
AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer
AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer
CP Wire
AstraZeneca
MedImmune
Imfinzi
non-small cell lung cancer
Flag link:
AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer
AstraZeneca
Imfinzi
non-small cell lung cancer
Flag link:
Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge
Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge
Endpoints
FDA
Advair
AstraZeneca
Imfinzi
clinical trials
Flag link:
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
Yahoo/Zacks.com
AstraZeneca
FDA
Imfinzi
non-small cell lung cancer
Flag link:
FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market
FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market
Endpoints
FDA
AstraZeneca
Imfinzi
lung cancer
Bavencio
Pfizer
Merck KGaA
Flag link:
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
BioPharma Dive
clinical trials
AstraZeneca
Mystic
Imfinzi
non-small cell lung cancer
Flag link:
AstraZeneca plans new pivotal lung cancer trial with Incyte
AstraZeneca plans new pivotal lung cancer trial with Incyte
Yahoo/Reuters
AstraZeneca
Incyte
clinical trials
Imfinzi
epacadostat
lung cancer
Flag link:
What's Behind AstraZeneca's September Rebound?
What's Behind AstraZeneca's September Rebound?
Motley Fool
AstraZeneca
Imfinzi
Flag link:
NewLink inks deal with AstraZeneca to test Imfinzi combo
NewLink inks deal with AstraZeneca to test Imfinzi combo
BioPharma Dive
NewLink Genetics
AstraZeneca
Imfinzi
indoximod
metastatic pancreatic cancer
Flag link:
ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
Fierce Pharma
ESMO
AstraZeneca
Imfinzi
lung cancer
Flag link:
AstraZeneca fights back in cancer with new hires, fast drug status
AstraZeneca fights back in cancer with new hires, fast drug status
Yahoo/Reuters
AstraZeneca
Imfinzi
immuno-oncology
Flag link:
AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B
AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B
Fierce Pharma
AstraZeneca
Merck
Lynparza
Imfinzi
Flag link:
AstraZeneca lung cancer immunotherapy trial failure sends shares plunging
AstraZeneca lung cancer immunotherapy trial failure sends shares plunging
Stat
AstraZeneca
Mystic
immuno-oncology
clinical trials
tremelimumab
Imfinzi
Flag link:
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Endpoints
investors
AstraZeneca
Pascal Soriot
Imfinzi
tremelimumab
immuno-oncology
clinical trials
Flag link:

Pages